ExonHit Presents Promising First Patient Results For EHT 0202, Its Alzheimer's Candidate Drug
Top-line Phase IIa clinical data released demonstrate that EHT 0202, ExonHit's lead candidate for the treatment of Alzheimer's disease, is safe and generally well tolerated in patients and that it could potentially enhance cognition in Alzheimer's disease patients.